Disparities in Inclusion of Racial, Ethnic Minority Groups in Prostate Cancer Clinical Trials

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 23, 2022

Media advisory: The full is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.5511?guestAccessKey=f799505c-99e1-4b63-a9b1-95df0244791e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=112322

 

About The Study: The results of this meta-analysis of 286 randomized clinical trials including 9,500 patients suggest that Black and Hispanic men are underrepresented in trials compared with their share of prostate cancer incidence. The representation of Black patients has consistently remained low during the past 2 decades. 

Authors: Irbaz Bin Riaz, M.B.B.S., M.S., of Harvard Medical School in Boston, is the corresponding author. 

 

(doi:10.1001/jamaoncol.2022.5511)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.